PD-1 inhibitors cause ILD in NSCLC patients with hypertension

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1925卷 / 1期
关键词：
D O I：
10.1007/s40278-022-23788-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11 / 11
相关论文
共 50 条
  • [1] PD-1 Inhibitors Raise Survival in NSCLC
    不详
    CANCER DISCOVERY, 2014, 4 (01) : 6 - 6
  • [2] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    Rothschild, S. I.
    Leger, P.
    Castellanos, E. L.
    Pillai, R. N.
    York, S. J.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [4] PD-1 inhibitors in patients with Hodgkin lymphoma
    Rossi, Cedric
    Casasnovas, Rene-Olivier
    EUROPEAN JOURNAL OF CANCER, 2022, 164 : 114 - 116
  • [5] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [6] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [7] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381
  • [8] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [9] ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors
    Park, W.
    Kwon, D.
    Desai, A.
    Florou, V.
    Saravia, D.
    Warsch, J.
    Chae, Y. K.
    Ishkanian, A.
    Jahanzeb, M.
    Mudad, R.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2004 - S2004
  • [10] Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC
    Poletes, C.
    Cheng, S. C.
    Zhan, L. J.
    Lee, J.
    Patel, D.
    Bradbury, P. A.
    Shepherd, F. A.
    Leighl, N. B.
    Sacher, A. G.
    Liu, G.
    Lau, S. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S95 - S96
12345